Clinical Trial Design Types
Clinical trials test whether interventions are safe, produce the intended biological effect and-importantly-improve patient outcomes in the settings where they will be used.
The choice of design determines which question the trial answers, the trade‑off between internal and external validity, and how results should influence practice or policy.
This section summarises common trial design types, places efficacy/effectiveness in a regulatory phase context, and gives practical appraisal and governance points for clinicians, with emphasis on emergency‑medicine relevance.
Core concepts (orienting)
- Internal validity: confidence that the observed effect is caused by the intervention in the study population (achieved by tight eligibility, standardisation, blinding).
- External validity (generalisability): how well results apply to routine patients and settings (achieved by broad eligibility, flexible delivery, multiple centres).
- Efficacy versus effectiveness: efficacy = can it work under ideal conditions; effectiveness = does it work in routine practice.
- Trial phases (regulatory frame):
- Phase I: first‑in‑human / safety; pharmacokinetics; high safety oversight and specific accreditation requirements for first‑in‑human work.
- Phase II: dose finding, proof‑of‑concept, early efficacy (often has explanatory features).
- Phase III: pivotal comparative trials demonstrating efficacy/safety to support regulatory approval (often more pragmatic).
- Phase IV: post‑marketing surveillance and real‑world studies.
- Design choices balance these concepts: explanatory approaches maximise internal validity; pragmatic approaches maximise external validity and decision relevance (see NICE guidance).